Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · IEX Real-Time Price · USD
4.080
-0.790 (-16.22%)
At close: Jul 2, 2024, 4:00 PM
4.300
+0.220 (5.39%)
After-hours: Jul 2, 2024, 7:34 PM EDT
Nuwellis Revenue
Nuwellis had revenue of $8.90M in the twelve months ending March 31, 2024, with 5.35% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.86M with 1.70% year-over-year growth. In the year 2023, Nuwellis had annual revenue of $8.86M with 3.76% growth.
Revenue (ttm)
$8.90M
Revenue Growth
+5.35%
P/S Ratio
0.24
Revenue / Employee
$150,763
Employees
59
Market Cap
2.10M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.86M | 321.00K | 3.76% |
Dec 31, 2022 | 8.54M | 622.00K | 7.85% |
Dec 31, 2021 | 7.92M | 480.00K | 6.45% |
Dec 31, 2020 | 7.44M | 1.93M | 35.02% |
Dec 31, 2019 | 5.51M | 513.00K | 10.26% |
Dec 31, 2018 | 5.00M | 1.45M | 40.67% |
Dec 31, 2017 | 3.55M | 2.26M | 175.64% |
Dec 31, 2016 | 1.29M | 1.23M | 2,084.75% |
Dec 31, 2015 | 59.00K | -236.00K | -80.00% |
Dec 31, 2014 | 295.00K | 236.00K | 400.00% |
Dec 31, 2013 | 59.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 407.00K | 183.00K | 81.70% |
Dec 31, 2009 | 224.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
cbdMD | 21.58M |
NovaBay Pharmaceuticals | 14.23M |
InMed Pharmaceuticals | 5.63M |
Tenon Medical | 3.21M |
Tivic Health Systems | 1.13M |
Aclarion | 60.05K |
NUWE News
- 6 days ago - Nuwellis Announces Reverse Stock Split - GlobeNewsWire
- 7 days ago - Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™ - GlobeNewsWire
- 21 days ago - DaVita, Nuwellis Extend Pilot Collaboration for Aquadex - Benzinga
- 26 days ago - Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase - GlobeNewsWire
- 7 weeks ago - Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida - GlobeNewsWire
- 7 weeks ago - Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy - GlobeNewsWire
- 2 months ago - Nuwellis, Inc. Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Nuwellis Announces Closing of $2.7 Million Public Offering - GlobeNewsWire